Global Pelvic Floor Electrical Stimulation Devices Market Size By Type (Mobile, Fixed), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Pelvic Floor Electrical Stimulation Devices Market was valued at USD 638 million in 2023 and is projected to reach USD 1.15 billion by 2031, growing at a CAGR of 7.5% during the forecast period from 2023 to 2031. The increasing prevalence of pelvic floor disorders, rising awareness about women's health, and growing geriatric population are major factors driving market growth. These devices play a crucial role in managing conditions like urinary incontinence, pelvic organ prolapse, and fecal incontinence by strengthening pelvic floor muscles through controlled electrical stimulation.

Drivers:

1. Rising Prevalence of Pelvic Floor Disorders:

A growing number of women and elderly individuals are experiencing pelvic floor dysfunction due to aging, childbirth, obesity, and surgery. The need for non-invasive and effective treatment solutions is significantly driving demand for electrical stimulation devices.

2. Increasing Awareness and Adoption of Non-Surgical Therapies:

There is a growing trend toward using pelvic floor stimulation devices as a non-invasive alternative to surgery and medication. Public health campaigns and recommendations from gynecologists and urologists are encouraging adoption.

3. Technological Advancements:

Innovations such as portable, app-connected, and home-use devices with personalized therapy modes are expanding the market, particularly among tech-savvy consumers seeking discreet treatment options.

Restraints:

1. High Cost and Limited Insurance Coverage:

The relatively high cost of advanced stimulation devices, along with inadequate reimbursement in certain countries, can hinder widespread adoption, particularly in developing regions.

2. Social Stigma and Low Diagnosis Rates:

Despite rising awareness, many individuals remain reluctant to seek help for pelvic floor disorders due to embarrassment or lack of awareness, leading to underdiagnosis and low treatment rates.

Opportunity:

1. Growing Geriatric Population and Women's Health Initiatives:

Global aging demographics, along with increased focus on women's health and wellness, are creating significant opportunities for manufacturers to expand their product reach and develop targeted solutions.

2. Expansion into Emerging Markets:

With healthcare systems improving in regions like Asia-Pacific and Latin America, there is strong potential for market growth driven by increasing access to medical devices and growing awareness.

Market by System Type Insights:

In 2023, Portable Electrical Stimulation Devices held the largest market share due to their convenience, affordability, and increasing use for home therapy. These devices are preferred by patients looking for privacy and cost-effective treatment solutions. Meanwhile, Stationary Clinical Units are widely used in hospitals and specialty clinics for more advanced therapy under medical supervision.

Market by End-use Insights:

Hospitals and Clinics accounted for the dominant share of the market in 2023. Their stronghold is attributed to better diagnostic facilities and availability of skilled professionals. However, the Home Care Settings segment is expected to witness the highest growth rate, fueled by the growing preference for remote healthcare and self-managed treatments.

Market by Regional Insights:

North America led the global market in 2023, driven by robust healthcare infrastructure, higher awareness, and a proactive approach to women's health. Europe followed closely due to strong public health programs and reimbursement schemes. Asia-Pacific is projected to be the fastest-growing region, propelled by expanding healthcare access, demographic shifts, and government-led health initiatives.

Competitive Scenario:

Prominent players in the market include Atlantic Therapeutics, Laborie, TensCare Ltd., Verity Medical Ltd., The Prometheus Group, InControl Medical, Zynex Medical, Medtronic plc, and NeuroTrac. These companies are focused on developing user-friendly, connected devices and are actively engaged in strategic partnerships, regulatory approvals, and geographic expansion.

Key Developments Include:

In 2023, Atlantic Therapeutics launched a next-gen app-integrated pelvic floor trainer featuring real-time muscle response feedback.

In 2024, TensCare Ltd. expanded into South America through distribution partnerships, targeting underserved markets.

In 2025, Medtronic plc received FDA clearance for a new device designed specifically for post-partum pelvic health rehabilitation.

Scope of Work – Global Pelvic Floor Electrical Stimulation Devices Market

Report Metric Details

Market Size (2023) USD 638 million

Projected Market Size (2031) USD 1.15 billion

CAGR (2023–2031) 7.5%

Market Segments System Type (Portable, Stationary), End-use (Hospitals, Homecare)

Growth Drivers Aging population, rise in non-surgical treatments, increased awareness

Opportunities Expansion in emerging markets, women's health focus, tech integration

FAQs:

1) What is the current market size of the Global Pelvic Floor Electrical Stimulation Devices Market?

The market was valued at USD 638 million in 2023.

2) What is the major growth driver of the Global Pelvic Floor Electrical Stimulation Devices Market?

Key growth is driven by rising awareness of pelvic floor health and increasing adoption of non-invasive treatment options.

3) Which is the largest region during the forecast period in the Global Pelvic Floor Electrical Stimulation Devices Market?

North America is expected to dominate due to strong healthcare systems and high awareness.

4) Which segment accounted for the largest market share in Global Pelvic Floor Electrical Stimulation Devices Market?

The Portable Electrical Stimulation Devices segment led the market in 2023.

5) Who are the key market players in the Global Pelvic Floor Electrical Stimulation Devices Market?

Key players include Atlantic Therapeutics, TensCare Ltd., Laborie, Verity Medical, InControl Medical, and Medtronic plc.